Table 1.
Baseline demographic factors
| Demographic factors | ALC (n = 208) | Placebo (n = 201) | P* |
|---|---|---|---|
| Age, mean (SD), y | 53.3 (9.9) | 51.9 (10.9) | .16 |
| Age < 60 y, No. (%) | 150 (72.1) | 146 (72.6) | .91 |
| Race, No. (%) | .32 | ||
| White | 160 (76.9) | 165 (82.1) | |
| Black | 18 (8.7) | 20 (10.0) | |
| Asian | 12 (5.8) | 8 (4.0) | |
| Pacific Islander | 4 (1.9) | 3 (1.5) | |
| Native American | 2 (1) | 0 (0.0) | |
| Unknown | 12 (5.8) | 5 (2.5) | |
| Hispanic, No. (%) | .47 | ||
| Yes | 21 (10.1) | 15 (7.5) | |
| No | 181 (87.0) | 177 (88.0) | |
| Unknown | 6 (2.9) | 9 (4.5) | |
| Taxane regimen, No. (%) | .91 | ||
| Weekly paclitaxel, 12 wk | 73 (35.1) | 68 (33.8) | |
| Biweekly paclitaxel for 4 cycles, 8 wk | 48 (23.0) | 51 (25.4) | |
| Biweekly paclitaxel for 6 cycles, 12 wk | 3 (1.4) | 5 (2.5) | |
| Every-3-wk docetaxel for 4 cycles, 12-wk TC | 51 (24.5) | 48 (23.9) | |
| Every-3-wk docetaxel for 6 cycles, 18-wk TAC or TC | 33 (15.9) | 29 (14.4) | |
| Performance Status, No. (%) | .86 | ||
| 0 | 156 (75) | 146 (73) | |
| 1 | 51 (25) | 54 (27) | |
| 2 | 1 (<1) | 1 (<1) | |
| Stage, No. (%) | .82 | ||
| I | 57 (27.4) | 50 (25.0) | |
| II | 110 (52.9) | 107 (53.5) | |
| III | 41 (19.7) | 43 (21.5) |
*
Baseline factors were compared by treatment groups using chi-square tests for categorical variables and t tests for continuous variables. Tests were two-sided. A = doxorubicin; C = cyclophosphamide; T = docetaxel.